Abou Issa Jamil, Vusqa Urwat, Behling Eric M, Budak-Alpdogan Tulin, Ghimire Sushil
Internal Medicine, Cooper University Hospital, Camden, USA.
Hematology and Medical Oncology, Cooper University Hospital, Camden, USA.
Cureus. 2025 Apr 2;17(4):e81602. doi: 10.7759/cureus.81602. eCollection 2025 Apr.
Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare but serious complication that poses significant diagnostic and therapeutic challenges. This article presents three cases of leptomeningeal involvement in patients with MM, highlighting the diverse clinical presentations, diagnostic approaches, and treatment strategies employed. The first case is a 54-year-old female who, after initial treatment and autologous hematopoietic stem cell transplant, developed CNS disease. Similarly, a 73-year-old female developed leptomeningeal involvement with progressive neurological symptoms. The third case describes a 63-year-old female with immunoglobulin (Ig)A lambda MM who developed CNS disease after treatment with daratumumab and radiation. In all three cases, leptomeningeal enhancement and atypical plasma cells were identified in cerebrospinal fluid (CSF), with treatment strategies including intrathecal chemotherapy, systemic therapy, radiation, and stem cell transplantation. Despite aggressive management, including novel agents and supportive care, all patients had poor outcomes, with two transitioning to hospice care. The article reviews the limited literature on CNS-MM, noting the lack of standardized treatment protocols and the need for further research. As the survival of MM patients improves, the incidence of CNS involvement is expected to rise, making the development of targeted therapies essential. These cases underscore the urgent need for further investigation into novel treatment options and the importance of early diagnosis and comprehensive management of CNS-MM.
中枢神经系统(CNS)受累于多发性骨髓瘤(MM)是一种罕见但严重的并发症,带来了重大的诊断和治疗挑战。本文介绍了3例MM患者的软脑膜受累情况,突出了其多样的临床表现、诊断方法及所采用的治疗策略。首例病例为一名54岁女性,在初始治疗及自体造血干细胞移植后出现CNS疾病。同样,一名73岁女性出现软脑膜受累并伴有进行性神经症状。第三例病例描述了一名63岁患有免疫球蛋白(Ig)A λ型MM的女性,在接受达雷妥尤单抗治疗及放疗后出现CNS疾病。在所有3例病例中,脑脊液(CSF)均发现软脑膜强化及非典型浆细胞,治疗策略包括鞘内化疗、全身治疗、放疗及干细胞移植。尽管采取了积极的治疗措施,包括使用新型药物及支持治疗,但所有患者预后均较差,其中2例转为临终关怀。本文回顾了关于CNS-MM的有限文献,指出缺乏标准化治疗方案以及进一步研究的必要性。随着MM患者生存率的提高,CNS受累的发生率预计将会上升,因此开发靶向治疗至关重要。这些病例强调了迫切需要进一步研究新型治疗选择,以及早期诊断和CNS-MM综合管理的重要性。